pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: ADHD

May 22, 2023

Corium's Novel ADHD Medication AZSTARYS (Serdexmethylphenidate and Dexmethylphenidate) Had No Clinically Significant Impact on Children's Weight and Height Growth Rate

Mar 13, 2023

Corium to Report Positive Data on ADHD Medication AZSTARYS (serdexmethylphenidate and dexmethylphenidate) at 2023 American Neuropsychiatric Association Annual Meeting and at 2023 National Association of Pediatric Nurse Practitioners Conference

Feb 22, 2023

Corium's Novel ADHD Medication AZSTARYS (serdexmethylphenidate and dexmethylphenidate) Shown Safe and Effective in Long-Term Study

Sep 13, 2022

Corium to Present Positive Data on ADHD Medication AZSTARYS (serdexmethylphenidate and dexmethylphenidate) and Alzheimer's Disease Medication ADLARITY (donepezil transdermal system) at Psych Congress 2022

Jun 1, 2022

Serdexmethylphenidate, a Prodrug of Dexmethylphenidate and Contained in Corium's ADHD Medication AZSTARYS (serdexmethylphenidate and dexmethylphenidate), Has Low Relative Potential for Abuse

Mar 28, 2022

Corium To Present at Academy of Managed Care Pharmacy: Fast-Acting AZSTARYS (serdexmethylphenidate and dexmethylphenidate) Significantly Improves Attention and Behavior in Children Aged 6 to 12 Years With ADHD

Feb 15, 2022

Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD

Nov 17, 2021

OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Oct 29, 2021

Significant ADHD Symptom Improvement with 30-Minute Onset and 13-Hour Duration of Efficacy Delivered by Once-Daily Corium Product AZSTARYS (serdexmethylphenidate and dexmethylphenidate) in Children Ages 6 to 12 Years

Jul 21, 2021

Corium Launches Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older

Apr 22, 2021

OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Oct 26, 2020

Cingulate Therapeutics Presents Results of Pivotal Phase 2 Clinical Trial for Lead ADHD Candidate CTx-1301 at the American Association of Child and Adolescent Psychiatry Annual Meeting

Jul 9, 2020

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada USA - English France - Français

Oct 28, 2019

Ironshore Pharmaceuticals Recognizes ADHD Awareness Month Through Partnership With CHADD

Oct 16, 2019

Ironshore Pharmaceuticals to Present Data at the 66th Annual AACAP Meeting

Aug 9, 2018

Ironshore Pharmaceuticals Announces FDA Approval of JORNAY PMTM (Methylphenidate) Extended-Release Capsules CII for the Treatment of ADHD

Apr 19, 2017

Ironshore Pharmaceuticals to Present Data at the 6th World Congress on ADHD

Dec 15, 2016

Ironshore Pharmaceuticals Announces FDA Acceptance of HLD200 New Drug Application for Treatment of ADHD

Oct 5, 2016

Ironshore Pharmaceuticals and CHADD to Raise Awareness about the Negative Impact of ADHD During the Early Morning Routine